
    
      This is a prospective, multi-center, single-arm study to evaluate safety and efficacy of the
      VenTouch System for treatment of subjects with functional MR enrolling up to 15 subjects who
      have been diagnosed with Grade 3-4 functional mitral valve regurgitation and deemed eligible
      per assessment by the inclusion/exclusion criteria. The duration of the study follow-up is 36
      months from the time of therapy adjustment. Data from this trial may be utilized in support
      of a CE study in Europe and/or a pilot IDE study in the U.S. Follow-up testing will be
      performed at 1, 3, 6, 12, 24, and 36 months post-therapy adjustment.
    
  